Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Total Non-Current Liabilities (2020 - 2024)

Relay Therapeutics (RLAY) has disclosed Total Non-Current Liabilities for 5 consecutive years, with $93.5 million as the latest value for Q4 2024.

  • On a quarterly basis, Total Non-Current Liabilities rose 18.7% to $93.5 million in Q4 2024 year-over-year; TTM through Dec 2024 was $93.5 million, a 18.7% increase, with the full-year FY2024 number at $93.5 million, up 18.7% from a year prior.
  • Total Non-Current Liabilities was $93.5 million for Q4 2024 at Relay Therapeutics, up from $90.8 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $126.0 million in Q3 2022 to a low of $36.5 million in Q4 2020.
  • A 5-year average of $83.8 million and a median of $84.3 million in 2024 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: soared 151.74% in 2022, then crashed 32.77% in 2023.
  • Relay Therapeutics' Total Non-Current Liabilities stood at $36.5 million in 2020, then skyrocketed by 65.25% to $60.4 million in 2021, then skyrocketed by 94.07% to $117.2 million in 2022, then plummeted by 32.77% to $78.8 million in 2023, then increased by 18.7% to $93.5 million in 2024.
  • Per Business Quant, the three most recent readings for RLAY's Total Non-Current Liabilities are $93.5 million (Q4 2024), $90.8 million (Q2 2024), and $84.3 million (Q1 2024).